Dr. Florian CLATOT

Année d’arrivée au Centre

2011

Formation

  • Habilitation à Diriger des Recherches, Faculté de Rouen
  • Thèse de Sciences, Faculté de Rouen
  • Thèse de Médecine, Faculté de Rouen
  • Ancien Elève de l’Ecole Normale Supérieure de Lyon (section Biologie)

Interventions pratiquées ou expertise

  • Expertise en cancérologie ORL et sénologique
  • Expertise en recherche clinique et translationnelle

Sociétés savantes

  • Membre de l’ASCO
  • Membre du GORTEC
  • Membre des groupes Unicancer Breast et Head Neck

Publications majeures

  • Genomics and precision surgery for head and neck squamous cell carcinoma. Cancer Lett. 2020 Apr 6;481:45-54.
  • Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer. Eur J Cancer. 2020 Jan 10;126:116-124.
  • Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy. Front Oncol. 2019 Jul 12;9:575
  • Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma. Oral Oncol. 2019 Jun;93:46-51.
  • Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients. Breast Cancer Res. 2018 May 16;20(1):40.
  • Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016 Nov 15;7(46):74448-74459.
  • Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer. 2015 Nov 15;137(10):2513-9.